SG10201808746QA - Methods for enhancing the efficacy of a tumor-directed immune response - Google Patents

Methods for enhancing the efficacy of a tumor-directed immune response

Info

Publication number
SG10201808746QA
SG10201808746QA SG10201808746QA SG10201808746QA SG10201808746QA SG 10201808746Q A SG10201808746Q A SG 10201808746QA SG 10201808746Q A SG10201808746Q A SG 10201808746QA SG 10201808746Q A SG10201808746Q A SG 10201808746QA SG 10201808746Q A SG10201808746Q A SG 10201808746QA
Authority
SG
Singapore
Prior art keywords
efficacy
enhancing
immune response
tumor
methods
Prior art date
Application number
SG10201808746QA
Inventor
Samir Khleif
Original Assignee
Augusta University Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Augusta University Research Institute Inc filed Critical Augusta University Research Institute Inc
Publication of SG10201808746QA publication Critical patent/SG10201808746QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001161—Caspases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001181—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

METHODS FOR ENHANCING THE EFFICACY OF A TUMOR-DIRECTED IMMUNE RESPONSE 5 As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen. 10 [Figure 1A.]
SG10201808746QA 2014-04-03 2015-04-02 Methods for enhancing the efficacy of a tumor-directed immune response SG10201808746QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461974781P 2014-04-03 2014-04-03

Publications (1)

Publication Number Publication Date
SG10201808746QA true SG10201808746QA (en) 2018-11-29

Family

ID=54241282

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608181YA SG11201608181YA (en) 2014-04-03 2015-04-02 Methods for enhancing the efficacy of a tumor-directed immune response
SG10201808746QA SG10201808746QA (en) 2014-04-03 2015-04-02 Methods for enhancing the efficacy of a tumor-directed immune response

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608181YA SG11201608181YA (en) 2014-04-03 2015-04-02 Methods for enhancing the efficacy of a tumor-directed immune response

Country Status (12)

Country Link
US (1) US10478491B2 (en)
EP (1) EP3126007B1 (en)
JP (1) JP6612252B2 (en)
KR (1) KR20170002410A (en)
CN (1) CN106457001B (en)
AU (1) AU2015240727A1 (en)
CA (1) CA2948054A1 (en)
ES (1) ES2774381T3 (en)
IL (1) IL248079A0 (en)
RU (1) RU2689162C2 (en)
SG (2) SG11201608181YA (en)
WO (1) WO2015153857A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
BR112018002570A2 (en) 2015-10-02 2018-10-16 Hoffmann La Roche bispecific antigen binding molecule, bispecific antibody, polynucleotides, ox40-specific binding antibody, pharmaceutical composition and method for inhibiting tumor cell growth in an individual
CN108883173B (en) 2015-12-02 2022-09-06 阿吉纳斯公司 Antibodies and methods of use thereof
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
CN110585131A (en) * 2019-09-20 2019-12-20 宁夏医科大学 Chemotherapy drug co-loaded 1-methyltryptophan immune prodrug micelle, preparation method and application thereof
PL241053B1 (en) 2020-06-09 2022-07-25 Wojskowa Akademia Techniczna Im Jaroslawa Dabrowskiego Platform for rail-road transport, especially wooden and metal logs
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN114515335A (en) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 Use of anti-OX 40 antibodies in the treatment of tumors or cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
WO2004019886A2 (en) * 2002-08-29 2004-03-11 Cytocure Llc Methods for up-regulating antigen expression in tumors
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
PT1877090E (en) 2005-05-06 2014-04-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
CA2695385A1 (en) * 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
NZ629913A (en) 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
ES2740358T3 (en) * 2012-02-06 2020-02-05 Providence Health & Services Oregon Method of monitoring cancer treatment with OX40 agonists
US20150157710A1 (en) * 2012-03-02 2015-06-11 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Dual ox40 agonist/il-2 cancer therapy methods

Also Published As

Publication number Publication date
WO2015153857A8 (en) 2016-10-13
EP3126007A4 (en) 2017-10-25
US10478491B2 (en) 2019-11-19
EP3126007B1 (en) 2019-12-11
AU2015240727A1 (en) 2016-11-10
JP2017511320A (en) 2017-04-20
RU2016142210A3 (en) 2018-11-13
EP3126007A1 (en) 2017-02-08
KR20170002410A (en) 2017-01-06
US20170182156A1 (en) 2017-06-29
IL248079A0 (en) 2016-11-30
JP6612252B2 (en) 2019-11-27
RU2689162C2 (en) 2019-05-24
CA2948054A1 (en) 2015-10-08
CN106457001B (en) 2021-02-02
RU2016142210A (en) 2018-05-04
SG11201608181YA (en) 2016-10-28
WO2015153857A1 (en) 2015-10-08
ES2774381T3 (en) 2020-07-20
CN106457001A (en) 2017-02-22

Similar Documents

Publication Publication Date Title
SG10201808746QA (en) Methods for enhancing the efficacy of a tumor-directed immune response
PH12017501127A1 (en) Antibodies targeting b-cell maturation antigen and methods of use
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
EA201692512A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT BY SYNTHETIC NANOSEMS AND INHIBITORS OF THE IMMUNE CONTROL POINT
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
MX2019009660A (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine.
NI201500062A (en) ADJUVANT THERAPY WITH KINASE INHIBITORS FROM THE TEC FAMILY
MX2017001406A (en) Flagellin-based agents and uses including effective vaccination.
EA201790180A1 (en) METHODS AND THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF TUMORS
EA201790398A1 (en) METHODS OF TREATING LIVER DISEASES
MX2016015363A (en) Combination therapies for the treatment of cancer.
MX2016006316A (en) Mtor inhibitors for enhancing the immune response.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
ES2681973T3 (en) Anti-tumor response against modified autoepitopes
EA201800148A1 (en) CHALLENGE VACCINE FOR CANCER TREATMENT
EA202090683A3 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
EA201692554A1 (en) MENICOCOCCY VACCINES
EA201790529A1 (en) NEW ANTIBODIES AGAINST MFI2 AND METHODS OF THEIR APPLICATION
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
NZ722600A (en) Methods of treating mild brain injury
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
PH12016502322A1 (en) Compounds and methods for preventing or treating malaria